
Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Wearable device company expands clinical research with GLP-1 study
- A major wearable device company teamed up with a university to launch a multi-year clinical trial to study whether the company’s continuous data can help track outcomes in patients receiving GLP-1 drugs or bariatric surgery.
- According to Fierce Healthcare, the study is part of the wearable device company’s broader push into clinical healthcare, using wearable data to connect measures such as sleep, activity and heart rate with outcomes including weight loss and treatment persistence.
HHS opens door to compounding six unapproved peptides
- The U.S. Department of Health and Human Services introduced an interim policy allowing pharmacies and physicians to compound six unapproved peptides, arguing that regulated access could reduce reliance on risky gray-market products.
- According to BioSpace, the policy has divided the industry. Compounding and peptide groups support expanded access, while others warn the peptides have not been proven safe or effective in clinical trials.
UK Autumn Budget unlocks over £1 billion in life sciences investment
- The UK chancellor announced more than £1 billion of new public-private life sciences investment across three major deals, backed by almost £70 million in government grant funding, including new facilities and research and development capacity, as reported by Mishcon.
- Commitments include more than £500 million for a global R&D hub in Manchester, over £300 million for a new Oxford facility and £200 million of investment in Loughborough, alongside an additional £20.4 billion announced for the National Wealth Fund.
AI company expands artificial intelligence’s role in drug development
- A major AI company’s early drug-development work shows AI being applied across the development lifecycle, not just molecule design. In a recent news release, the company announced that its partnerships have produced early gains in antibody design and optimization, regulatory documentation, manufacturing review and clinical-trial planning.
- The company’s broader goal is to embed its platform throughout drug development to reduce scientific, operational, and administrative bottlenecks. Most results remain preclinical, but the company is expanding into clinical development, running its own rare-disease programs, and offering tools to broaden adoption across the industry.
New COINS Act rules put China biotech investments under scrutiny
- The U.S. Department of Treasury proposed expanding Comprehensive Outbound Investment National Security (COINS) Act restrictions to biotechnology, which could block certain U.S. equity investments, joint ventures and investments involving Chinese biotechs.
- According to Fierce Biotech, traditional drug licensing and fee-for-service R&D deals would largely remain allowed permitted. However, industry groups warn overly broad rules could hurt U.S. biotech investment, partnerships and competitiveness.
RSM UK contributor: James Blackwell

